WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Cleaning Validation for Pharmaceutical Manufacturing
I'm For Real
Enter your details once to access all our information and resources
Biotest is a company specialising in innovative hematology and immunology products with the holistic approach of a global pharmaceutical.
whitePaper | October 4, 2022
Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative
whitePaper | July 7, 2022
The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.
whitePaper | January 1, 2020
With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.
whitePaper | December 13, 2022
A recent e-symposium presented insights into the latest research and innovative solutions to help shorten timeto-market, reduce development costs, increase yield, and assure quality and pharmacopoeia compliance throughout the drug development process.
whitePaper | November 24, 2022
Today’s pharmaceutical industry is facing big expectations and opportunities. Tasked with developing and manufacturing effective therapeutics and vaccines for an ongoing global pandemic,
whitePaper | July 13, 2023
Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE